R&D A certificate of analysis should be evidence, not a sales do... Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
Digital Better analytics leads to fewer regulator questions Stronger data analytics is cutting the number of questions regulators ask about intensified processes.
Market Access Biotech funding has returned. The bar has moved with it. For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.